---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-000857"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T15:44:13.505452+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Entera Bio-OPKO collaboration: oral GLP-1/glucagon tablet, $8M equity investment

## Summary
- OPKO purchased 3,685,226 Entera shares at ~$2.17/share ($8M) to fund Entera's 40% development cost share through Phase 1.
- Profit/cost split initially 60% OPKO / 40% Entera; opt-out after Phase 1 yields 85%/15% with OPKO funding.
- Parties expect to file IND with FDA later in 2025 for oral tablet combining OPK-88006 and Entera's N-Tab™ technology.
- OPKO subject to 12-month lockup on shares and 24-month standstill on acquiring additional Entera equity.
- Preclinical data reported September 2024 showed favorable pharmacodynamic and pharmacokinetic profiles.

## SEC filing metadata
- accession: 0001178913-25-000857
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891325000857/0001178913-25-000857-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891325000857/zk2532871.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-000857
- JSON: https://secwatch.observer/filing/0001178913-25-000857.json
- Plain text: https://secwatch.observer/filing/0001178913-25-000857.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.